News

Late in 2015, the company closed on a $50m Series A round, and completed its $100m Series B round this week. The most recent round was led by

The alliance will evaluate the potential for combining Astex’s guadecitabine (SGI-110) small molecule DNA hypomethylating agent with Genentech’s atezolizumab investigational anti-PD-L1 monoclonal antibody. The safety and pharmacology of

Ibrance is an oral inhibitor of CDKs 4 and 6, which are important regulators of the cell cycle that trigger cellular progression. The study met its primary endpoint

LAT Pharma brings a promising new therapeutic opportunity to NanoAntibiotics. Earlier this year LAT Pharma met with the FDA to discuss a submission for a novel therapy to

The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators, CGEN-15001T and CGEN-15022. In December 2015, the Company

This will expand the original partnership agreement signed on April 2015, from four to five products, and adds a separate agreement which allows Vitruvias to buy in to

The companies will target several G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology. The deal will see Heptares apply its StaR platform for the creation of

Labeling negotiations are now underway. The FDA extended the original action date of 17 January twice to enable for complete review. Sustol’s long-acting formulation is based on Heron’s

The designation was based on data from the ongoing Phase Ib Keynote-013 and Phase II Keynote-087 studies evaluating the drug as a single agent in patients with cHL,